Morgan Lewis has advised MPM Capital, a life-sciences venture capital firm investing in early-stage therapeutics companies based in Cambridge, MA, and Brisbane, CA, on the closing of its seventh venture fund, BioVentures 2018 (BV2018).
MPM is currently investing out of BV2018 and its two oncology-only funds with a total of more than USD1 billion in capital.
With BV2018, MPM will continue to create and invest in innovative companies developing breakthrough therapies to treat severe unmet medical needs. The fund will focus on disruptive scientific developments across multiple therapeutic areas, including oncology, immunology, and neuroscience as well as emerging modalities of cell, gene, and nucleic acid therapies.
MPM Capital was represented by partner Steve Giordano.
